Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus (SLE or lupus). At least 5 million people worldwide are living with lupus, one of the most complex autoimmune diseases. It's difficult to diagnose and even more challenging to treat. The condition is associated with a range of debilitating symptoms that can fluctuate over time, including painful or swollen joints, extreme fatigue, unexplained fever, skin rashes, and organ damage. Up to 50% of SLE patients experience irreversible organ damage within five years of diagnosis and this damage is associated with a poor long-term prognosis and early mortality.

Nearly two years since its massive 1.2 trillion transistor Wafer Scale Engine chip debuted at Hot Chips, Cerebras Systems is announcing its second-generation technology (WSE-2), which its says packs twice the performance into the same 8″x8″ silicon footprint. "We're going bigger, faster and better in a more power efficient footprint," Cerebras Founder and CTO Andrew Feldman told HPCwire ahead of today's launch. With 2.6 trillion transistors and 850,000 cores, the WSE-2 more than doubles the elements on the first-gen chip (1.2 trillion transistors, 400,000 cores). The new chip, made by TSMC on its 7nm node, delivers 40 GB of on-chip SRAM memory, 20 petabytes of memory bandwidth and 220 petabits of aggregate fabric bandwidth. Gen over gen, the WSE-2 provides about 2.3X on all major performance metrics, said Feldman.

British company Exscientia has been working with several pharmaceutical companies (including Sanofi, GlaxoSmithKline, and Roche), offering its artificial intelligence system to aid the drug discovery process. With the new announcement, Bayer are to back the project with €240 million ($266 million) over the course of three years. The focus of this digital transformation of the medication development process will be on the application of artificial intelligence to speed up the discovery of small molecule drug candidates. The drug candidates will have targets linked to oncology and cardiovascular disease. The deal between the two companies, as PharmaPorum reports, will see Bayer owning the rights to the compounds and Exscientia will receive royalties relating to future sales.

UK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking to use its platform to find new cardiovascular and cancer drugs. Bayer is pledging up to €240 million ($266 million) in upfront fees, ongoing research funding and clinical milestone payments under the terms of the three-year deal. The collaboration will use AI to accelerate discovery of small molecule drug candidates against targets in oncology and cardiovascular disease, with Bayer claiming rights to the compounds and Dundee-based Exscientia eligible for royalties on sales if they reach the market. Cancer and heart disease are at the forefront of Bayer's R&D focus along with women's health, haematology and ophthalmology. For eight-year-old Exscientia, Bayer joins a growing list of drugmakers who see its AI platform as a way to accelerate drug discovery and improve drug development productivity, potentially trimming years off the current 12 to 15 year cycle from early research to marketed product.

Artificial Intelligence (AI) and machine learning enter the research mainstream of biopharmaceutical companies, such as GlaxoSmithKline (GSK). GlaxoSmithKline (GSK) is creating a data-focused culture and a global machine-learning team. GlaxoSmithKline's (GSK's) data-first approach to drug discovery and development comes directly from chief executive officer (CEO) Emma Walmsley and chief scientific officer (CSO) Hal Barron. Their goal is doubling the chance of successful medicines being produced by using genetically validated targets. And that demands a strong team in artificial intelligence and machine learning (AI/ML).

Big data could be the future of the new antibiotic in the health care industry to enhance the patient medical care. Big data is shifting the paradigm by creating a new data-driven health care industry perfecting the precision on performing the surgery based on the data points built by big data analytics. Big data analytics tools are aiding corporations in developing new medicine every day with data science more accurately. According to a modern medical research estimate, the pharmaceutical product cost from the lab to the consumer is around $2.6 billion dollars. McKinsey, research estimated big data analytics tools would lower the health care industry costs to the tune of $493 billion dollars.

On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe. The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.

Most people don't seem to want to click on Web ads. Do they want to talk to them? Maybe if Watson-- IBM IBM 0.65 % 's supercomputer perhaps best known for its Jeopardy prowess--was the one talking back? The media company, all of which was acquired by IBM last October except for its traditional TV channel, is planning to roll out digital ads that people can communicate with this fall. Using Watson's artificial intelligence software, advertisers will be able to produce display ads that invite people to ask Watson questions about their products, either by speaking or typing into a search box.